Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Lantus Loss Drags Down Sanofi's Diabetes Franchise

This article was originally published in Scrip

Executive Summary

A nearly 20% drop in US sales of Sanofi's top-seller Lantus was largely to blame for a 6.6% fall in its diabetes franchise sales in the third quarter, leading the French pharma to lower its forecasts for its leading therapy segment.

Advertisement

Related Content

Sanofi CEO Upbeat Despite Medivation M&A Miss, Sarilumab Diss
Sanofi Seeks Medivation Board Overhaul As Buyout Bid Remains Rejected

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register